Form 483

Takeda Pharmaceutical Company Limited Form 483, 2012-08-02

FDA issued a Form 483 to Takeda Pharmaceutical Company Limited on 2012-08-02 with 7 public-safe observations.

483· Form 483 issued7 observations

Takeda Pharmaceutical Company Limited · Yodogawa-Ku, Japan · Issued August 2, 2012

Overview

  • 7 public-safe observations are available for this inspection.
  • 7 structured CFR citations are represented.
  • 2 investigators are tied to this Form 483.

Inspectional observations

Each observation cites the regulation FDA found the firm out of compliance with.

2 Aug 2012
21 CFR 211.67(b)

Written procedures fail to include

Cited by Ileana Barreto-Pettit, Juanita P Versace

2 Aug 2012
21 CFR 211.68(a)

Calibration/Inspection/Checking not done

Cited by Ileana Barreto-Pettit, Juanita P Versace

2 Aug 2012
21 CFR 211.110(a)

Control procedures to monitor and validate performance

Cited by Ileana Barreto-Pettit, Juanita P Versace

2 Aug 2012
21 CFR 211.113(b)

Procedures for sterile drug products

Cited by Ileana Barreto-Pettit, Juanita P Versace

2 Aug 2012
21 CFR 211.160(a)

Following/documenting laboratory controls

Cited by Ileana Barreto-Pettit, Juanita P Versace

Inspected site

Inspection team

Cited regulations

CFR citations associated with this Form 483.

CitationWhat it coversCited
21 CFR 211.110(a)Cited across public-safe Form 483 observations1x
21 CFR 211.113(b)Cited across public-safe Form 483 observations1x
21 CFR 211.160(a)Cited across public-safe Form 483 observations1x
21 CFR 211.165(e)Cited across public-safe Form 483 observations1x
21 CFR 211.192Cited across public-safe Form 483 observations1x
21 CFR 211.67(b)Cited across public-safe Form 483 observations1x
21 CFR 211.68(a)Cited across public-safe Form 483 observations1x

Full 483 report

Get the verbatim text of all 7 observations

Every observation in full, so your team sees exactly what was cited and how it was answered.

  • The site's full inspection history around this Form 483
  • Whether these citations escalated to a warning letter
  • The investigators involved and the citations they repeat elsewhere